ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib vs placebo in patients with advanced cholangiocarcinoma with an isocitrate dehydrogenase 1 (IDH1) mutation
Ghassan K. Abou-Alfa, et al.
演題レポート
Proffered Paper Session
#LBA11
食道癌
Nivolumab Versus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma: The ATTRACTION-3 Study
Cho B. Chul, et al.
#LBA30
大腸癌
Analysis of circulating tumor DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: prognostic and predictive value for adjuvant treatment duration
Julien Taieb, et al.
#LBA32
大腸癌
Encorafenib plus Cetuximab With or Without Binimetinib for BRAF V600E-Mutant Metastatic Colorectal Cancer: Expand Results from a Randomized, 3-Arm, Phase 3 Study vs. the Choice of Either Irinotecan or FOLFIRI plus Cetuximab (BEACON CRC)
Josep Tabernero, et al.
#LBA38
肝細胞癌
CheckMate 459: A Randomized, Multi-Center Phase 3 Study of Nivolumab vs Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma
Thomas Yau, et al.
#LBA41
胃癌
A Phase III open label randomized study of neoadjuvant chemotherapy with docetaxel, oxaliplatin and S-1 (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1 for resectable advanced gastric cancer (PRODIGY Study)
Yoon-Koo Kang, et al.
#LBA43
胃癌
Randomized phase 3 ANGEL study of rivoceranib （apatinib） + best supportive care （BSC） vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ?2 prior chemotherapy regimens
Yoon-Koo Kang, et al.
#LBA44
胃癌
Pembrolizumab With or Without Chemotherapy vs Chemotherapy in Patients With Advanced G/GEJ Cancer Including Outcomes According to Microsatellite Instability-High Status in KEYNOTE-062
Kohei Shitara, et al.
Poster Discussion Session
#526PD
大腸癌
TRIUMPH: Primary Efficacy of a Phase II Trial of Trastuzumab (T) and Pertuzumab (P) in Patients (pts) with Metastatic Colorectal Cancer (mCRC) with HER2 (ERBB2) Amplification (amp) in Tumor Tissue or Circulating Tumor DNA (ctDNA): A GOZILA Sub-study
Yoshiaki Nakamura, et al.
#533PD
大腸癌
BACCI: A Phase II Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Capecitabine Bevacizumab plus Atezolizumab or Placebo in Refractory Metastatic Colorectal Cancer: An ACCRU Network Study
Niharika B. Mettu, et al.
#674PD
胃癌
Perioperative FLOT + anti-PD-L1 Avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma: safety and biomarker data from the ICONIC trial safety run-in
Michael Davidson, et al.
Poster Display Session
#571P
大腸癌
Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study (C3)
Takeshi Nagasaka, et al.
#790P
胃癌
A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604)
Daisuke Takahari, et al.
#820P
胃癌
Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)
Yu Sunakawa, et al.
by European Society for Medical Oncology
